April 22, 2021 -- The Leukemia & Lymphoma Society Therapy Acceleration Program (LLS TAP) announced five new investments aimed at speeding the development of new and improved immunotherapies for the treatment of blood cancers.
The investments include three companies that have novel immunotherapies in early human clinical trials and two companies with promising programs in preclinical development for blood cancers: Caribou Biosciences, NexImmune, Immune-Onc Therapeutics, Carisma Therapeutics, and Abintus Bio.
LLS has dedicated more than $100 million over the past several decades, through both grants and TAP investments, to advancing pioneering approaches that harness cellular immunotherapies to fight blood cancers.
Copyright © 2021 scienceboard.net